Multiple Tumor Types

Viewing Page 4 of 6 | Showing Results 31 - 40 of 54

A Phase Ia/Ib Open-label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors

This is a Phase Ia/Ib, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 (ATR Inhibitor) in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

This is a modular, phase I/ phase 1 b, open-label, multicentre study of AZD6738 administered orally in combination with cytotoxic chemotherapy...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

John Wayne Cancer Institute Biospecimen Repository

Jose Esteban, M.D.
  • Disney Family Cancer Center (DFCC)
  • Providence Los Angeles Research Center
  • Providence St. Joseph Medical Center (PSJMC)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of an investigational product in Subjects with Radioiodine-Refractory Differentiated...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase I, first-in-human, dose-escalation study to evaluate the safety and immunologic response after administration of HS-130 in combination with HS-110 (viagenpumatucel-L) in patients with solid tumors refractory to standard care

This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in...

Rachel Sanborn, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

John Wayne Cancer Institute Biospecimen Repository Protocol

When cancer patients undergo procedures such as biopsies or surgery in which malignant tissue is removed for diagnostic or therapeutic purposes, it...

Jennifer Linehan, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

This is a first-in-human, Phase 1 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety,...

Jacob Thomas, M.D.
  • Hoag Research
  • xSJH Southern California

ABSCOPAL An observational study to assess the anti-tumor response in non-irradiated lesions (Abscopal effect) in patients with metastatic solid tumors who receive radiation while on immunotherapy.

To evaluate the rate of response in non-irradiated lesions in patients receiving radiation while on immunotherapy. This is measurable by RECIST...

Peter Jiang, M.D., Ph.D.
Viewing Page 4 of 6 | Showing Results 31 - 40 of 54